Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Schuitemaker

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
AIDS (London, England)|January 12, 2001
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infectionH Putter, J M Prins, S Jurriaans, et al.
AIDS (London, England)|August 26, 1998
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapyG J Weverling, J M Lange, S Jurriaans, et al.
The Journal of Experimental Medicine|April 1, 1995
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomaticsM R Klein, C A van Baalen, A M Holwerda, et al.
The Journal of Hospital Infection|July 3, 2007
Resistance of surface-dried virus to common disinfection proceduresF G Terpstra, A E van den Blink, L M Bos, et al.
Annals of Internal Medicine|February 12, 1998
Association between CCR5 genotype and the clinical course of HIV-1 infectionA M de Roda Husman, M Koot, M Cornelissen, et al.
Lancet (London, England)|July 31, 1998
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) studyM H Reijers, G J Weverling, S Jurriaans, et al.
The Journal of Clinical Investigation|December 31, 1997
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectivelyA B van't Wout, L J Ran, M D de Jong, et al.
The Journal of General Virology|January 8, 1999
Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzeesW M Bogers, W H Koornstra, R H Dubbes, et al.
AIDS (London, England)|December 22, 1999
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapyJ M Prins, S Jurriaans, R M van Praag, et al.
AIDS (London, England)|August 26, 1998
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapyR M Hoetelmans, M H Reijers, G J Weverling, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
AIDS (London, England)|January 12, 2001
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infectionH Putter, J M Prins, S Jurriaans, et al.
AIDS (London, England)|August 26, 1998
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapyG J Weverling, J M Lange, S Jurriaans, et al.
The Journal of Experimental Medicine|April 1, 1995
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomaticsM R Klein, C A van Baalen, A M Holwerda, et al.
The Journal of Hospital Infection|July 3, 2007
Resistance of surface-dried virus to common disinfection proceduresF G Terpstra, A E van den Blink, L M Bos, et al.
Annals of Internal Medicine|February 12, 1998
Association between CCR5 genotype and the clinical course of HIV-1 infectionA M de Roda Husman, M Koot, M Cornelissen, et al.
Lancet (London, England)|July 31, 1998
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) studyM H Reijers, G J Weverling, S Jurriaans, et al.
The Journal of Clinical Investigation|December 31, 1997
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectivelyA B van't Wout, L J Ran, M D de Jong, et al.
The Journal of General Virology|January 8, 1999
Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzeesW M Bogers, W H Koornstra, R H Dubbes, et al.
AIDS (London, England)|December 22, 1999
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapyJ M Prins, S Jurriaans, R M van Praag, et al.
AIDS (London, England)|August 26, 1998
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapyR M Hoetelmans, M H Reijers, G J Weverling, et al.
Pageof 10